PipelineReview.com. Biopharmaceutical News & Clinical Trials
WEBPipelineReview.com is powered by La Merie Business Intelligence For immediate assistance, please call us during business hours: Mon-Fri 10:00am - 05:00pm; GMT+01 La Merie Publishing - Ulrich Martin Veinat Puigsec - Can Magí s/n | 17862 Vallfogona de Ripollès | Spain | T +34-87-200 1365 | Email [email protected]
MiNA Therapeutics Enters Research Collaboration with Nippon …
WEBApr 5, 2024 · –Collaboration includes licensing agreement option based on early-stage preclinical outcomes. LONDON, UK I April 04, 2024 I MiNA Therapeutics, the pioneer of small activating RNA (RNAa) therapeutics, today announced a research collaboration and licensing agreement option with Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; Headquarters: Kyoto; President: Toru Nakai), an innovation-driven ...
Immorna Biotherapeutics Receives U.S. FDA IND Clearance to …
WEBJul 9, 2024 · MORRISVILLE, NC, USA I July 8, 2024 I Immorna Biotherapeutics, Inc. (Immorna), a clinical stage biotechnology company developing both self-replicating and conventional mRNA-based therapeutics and vaccines, announced today that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for JCXH-211 intravenous (IV), a novel, first-in-class self ...
Asha Therapeutics Announces the Nomination of a Novel Intra …
WEBApr 2, 2024 · CINCINNATI, OH, USA I April 01, 2024 I Asha Therapeutics (Asha) (www.ashatherapeutics.com), a life sciences company designing de novo disease modifying medicines for neurodegenerative diseases with high unmet medical need, announced today the nomination of a development candidate, ASHA-624 targeting SARM1 as a potential disease modifying therapy for Amyotrophic Lateral Sclerosis (ALS) with ...
Mediar Advances First-in-Class Fibrosis Portfolio to the Clinic with ...
WEBMay 6, 2024 · Phase 1 study of MTX-463 initiated after FDA Clearance of IND. IND-enabling studies completed for second antibody program with Phase 1 expected to start in Q3
Merck Provides Update on Phase 3 KEYLYNK-006 Trial
WEBMar 22, 2024 · RAHWAY, NJ, USA I March 21, 2024 I Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the Phase 3 KEYLYNK-006 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with maintenance LYNPARZA, a PARP inhibitor, did not meet its dual primary endpoints of overall survival (OS) and progression-free survival (PFS) for the first-line ...
Bristol Myers Squibb Announces CheckMate -9DW Trial Evaluating …
WEBMar 20, 2024 · Opdivo plus Yervoy demonstrates statistically significant and clinically meaningful improvement in overall survival compared to investigator’s choice of sorafenib or lenvatinib. PRINCETON, NJ, USA I March 20, 2024 I Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 CheckMate -9DW trial evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment for patients ...
Zealand Pharma announces positive topline results from 13-week …
WEBSep 10, 2024 · Placebo-adjusted reductions in body weight of up to a mean of 8.3% with dapiglutide after 13 weekly doses; Dapiglutide treatment with doses up to 13 mg was assessed to be safe and well-tolerated with gastrointestinal adverse events consistent with the profile reported with other incretin-based therapies
Tirzepatide reduced the risk of developing type 2 diabetes by 94
WEBAug 21, 2024 · 176-week SURMOUNT-1 Phase 3 study in adults with pre-diabetes is the longest completed trial of tirzepatide to date. Tirzepatide resulted in sustained weight loss through the treatment period, averaging a 22.9% decrease in body weight with the
Stealth BioTherapeutics Announces First Patient Enrolled in Global ...
WEBJun 6, 2024 · NEEDHAM, MA, USA I June 5, 2024 I Stealth BioTherapeutics Inc. (the “Company” or “Stealth”), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that it has enrolled and dosed its first patient in the ReNEW trial (NCT06373731) as part of its Phase 3 ...
Skip to content